Bristol Myers Squibb (BMY) suffered a setback in the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten).The phase III study was evaluating Camzyos for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy (nHCM).The dual-primary endpoints for the trial were to examine changes from baseline in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-23 CSS) and peak oxygen consumpt ...